TrialProgressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Trial details
- Registry ID
- NCT06360419
- Phase
- Phase 3
Drug research
Solriamfetol 300 mg
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419 | AXSM | Phase 3 | Completed | 2024-12-31Actual |
| Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)NCT06568367 | AXSM | Phase 3 | Recruiting | 2026-12Estimated |
| A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)NCT05972044 | AXSM | Phase 3 | Completed | 2025-02-07Actual |
| Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolNCT06413433 | AXSM | Phase 3 | Recruiting | 2026-12Estimated |
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Trial details
- Registry ID
- NCT06568367
- Phase
- Phase 3
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Trial details
- Registry ID
- NCT05972044
- Phase
- Phase 3
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Trial details
- Registry ID
- NCT06413433
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |